Researchers matched food intake between treated and untreated male and female rats to separate drug effects on the microbiome from diet effects.
Recap by typeshit. Full story at News-Medical.Net.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Fractyl will prioritize weight maintenance after GLP-1 treatment, while EyePoint narrows in on diabetes-related vision loss.
Researchers from WCVM and USask Medicine used the Canadian Light Source to study how an antimicrobial peptide forms a pore structure.
Loading…